Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180684 · ClinicalTrials.gov registry record · Phase 2
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
A Phase 2 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03180684 is a Phase 2 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT03180684, a Phase 2 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of an investigational immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar high-grade squamous intraepithelial lesion (HSIL) \[vulval intraepithelial neoplasia 2 or 3 (VIN 2 or VIN 3)\] associated with human papilloma virus (HPV) types 16 and/or 18. VGX-3100 is being assessed as an alternative to surgery with the potential to clear the underlying HPV infection. For more information visit our study website at: www.VINresearchstudy.com
Interventions
- BIOLOGICAL VGX-3100
- DRUG Imiquimod 5% Cream
- DEVICE CELLECTRA™ 2000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-08-31 |
| Est. Completion | 2020-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03180684
The ClinicalTrials.gov registry entry for NCT03180684 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which VGX-3100 is the first listed.
NCT03180684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03180684 about?
NCT03180684 is a clinical study titled "Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)". The purpose of this study is to test the safety and efficacy of an investigational immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar high-grade squamous intraepithelial lesion (HSIL) \[vulval intraepithelial neoplasia 2 or 3 (VIN 2 or VIN 3)\] associated with hum...
What is the current status of trial NCT03180684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2017-08-31. Estimated completion is 2020-12-18.
What interventions are being tested in trial NCT03180684?
The interventions under investigation include: VGX-3100 (BIOLOGICAL), Imiquimod 5% Cream (DRUG), CELLECTRA™ 2000 (DEVICE).
Who is sponsoring clinical trial NCT03180684?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.